Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush

This article was originally published in PharmAsia News

Executive Summary

More than 50 biotechs in China are now developing immuno-oncology assets centered mainly on the checkpoint inhibitor PD-1, meaning the emerging and promising treatment area is quickly becoming a crowded battlefield, insiders at a recent ChinaBio partnering event cautioned.

You may also be interested in...



Zai Lab Soars On Nasdaq Debut

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m

WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.

2016 Review: Pricing, R&D Issues Dominate China Commercial Arena

2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel